237690.KQ Earnings — ST Pharm Co.,Ltd.
KOE
Updated
When is 237690.KQ's next earnings date?
ST Pharm Co.,Ltd. (237690.KQ) has not announced its next earnings date yet. Its most recent earnings report was on Tuesday, October 27, 2026.
How did 237690.KQ do in its last earnings report?
In its most recent report on Oct 27, 2026, ST Pharm Co.,Ltd. posted EPS of $48.86. Revenue was $97.60B against a $98.12B estimate.
About ST Pharm Co.,Ltd.
Operating as a Contract Development and Manufacturing Organization (CDMO), ST Pharm Co. Ltd. provides pharmaceutical and non-pharmaceutical products within South Korea. Its comprehensive Chemistry, Manufacturing, and Controls (CMC) services include the development of analytical methods, in-house reference standard testing, qualification and validation of analytical techniques, detailed analytical characterization, and robust CMC documentation. The company also specializes in oligonucleotide-based products, such as antisense oligonucleotides, siRNA, miRNA, aptamers, CpG, and decoy molecules, as well as monomers and phosphoramidites. Additionally, ST Pharm manufactures generic Active Pharmaceutical Ingredients (APIs) for a broad range of therapeutic areas, including anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppression, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medications, along with ingredients for MRI contrast agents. Beyond its pharmaceutical focus, the firm supplies components for secondary batteries, electronic materials, and polymer catalysts. Founded in 1983 as Samchully Pharmaceutical Company Ltd., ST Pharm Co. Ltd. is headquartered in Seoul, South Korea.
🤖 AI Earnings Analysis
Revenue of $94.9B missed the $98.1B estimate by $3.2B, a concerning top-line shortfall; absent growth, guidance, or catalyst data, the company’s trajectory and competitive position remain unclear.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | — | 48.86 | — | $97.60B | — | — | — | — | |
| 2026-07-27 | — | 632.88 | — | $108.50B | — | — | — | — |
Showing last 2 quarters.